The stock of 3D Signatures Inc (CVE:DXD) hit a new 52-week high and has $1.56 target or 98.00% above today’s $0.79 share price. The 6 months bullish chart indicates low risk for the $35.51M company. The 1-year high was reported on Nov, 7 by Barchart.com. If the $1.56 price target is reached, the company will be worth $34.80M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 756,315 shares traded hands or 1076.37% up from the average. 3D Signatures Inc (CVE:DXD) has risen 6.00% since October 8, 2016 and is uptrending. It has outperformed by 4.04% the S&P500.
More notable recent 3D Signatures Inc (CVE:DXD) news were published by: Marketwired.com which released: “3D Signatures Inc. Announces Closing of Qualifying Transaction” on September 09, 2016, also Finance.Yahoo.com with their article: “3D Signatures Inc. Appoints Jason Flowerday as New CEO” published on September 27, 2016, Marketwired.com published: “3D Signatures Inc. and Plicit Capital Corp. Increase Minimum Financing and …” on May 26, 2016. More interesting news about 3D Signatures Inc (CVE:DXD) were released by: Marketwired.com and their article: “3D Signatures Inc. Commences Trading September 13th Under the Symbol (TSX …” published on September 12, 2016 as well as Marketwired.com‘s news article titled: “3D Signatures Inc. and Plicit Capital Corp. Execute Definitive Licencing and …” with publication date: July 21, 2016.
3D Signatures Inc, formerly Plicit Capital Corp, is a Canada personalized medicine firm with a software platform based on the three-dimensional analysis of telomere organization. The company has a market cap of $35.51 million. The Company’s software technology and prognostic methodology targets various diseases that demonstrate genomic instability, including cancer and neurological disorders. It currently has negative earnings. It is engaged in developing over five diagnostic and prognostic products for cancers and neurological disorders, including 3D Telo-PC, 3D Telo-RS, 3D Telo-MM, 3D Telo-BC, 3D Telo-LC and 3D Telo-AD.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.